23andMe Holding Co. Stock price

Equities

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
0.4709 USD +6.11% Intraday chart for 23andMe Holding Co. -12.52% -48.45%
Sales 2024 * 217M Sales 2025 * 265M Capitalization 227M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 1.05 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.86 x
P/E ratio 2024 *
-0.43 x
P/E ratio 2025 *
-0.8 x
Employees 793
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.42%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : 23andMe Holding Co., Q3 2024 Earnings Call, Feb 07, 2024
Earnings Flash (ME) 23ANDME Reports Q3 Revenue $44.7M, vs. Street Est of $56.3M MT
23andMe Holding Co. Reports Goodwill Impairment for the Third Quarter Ended December 31, 2023 CI
23andMe Holding Co. Provides Earnings Guidance for the Year Ending March 31, 2024 CI
23andMe Holding Co. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
23andMe Holding Co. Announces U.S. Food and Drug Administration Clears Investigational New Drug Application for 23ME-01473 CI
North American Morning Briefing : Big Tech Weighs on Stock Futures DJ
23andMe Holding Co. Announces Further Expansion of 23ME-00610 Phase 1/2a Clinical Trial in Advanced Neuroendocrine and Ovarian Cancer Patient Cohorts CI
23andMe Holding Co.(NasdaqGS:ME) dropped from S&P Health Care Services Select Industry Index CI
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Desktop Metal Poised to Rise, Ubiquiti to Decline MT
Alibaba Group Holds Stock in Nine U.S. Listed Companies MT
Transcript : 23andMe Holding Co., Q2 2024 Earnings Call, Nov 08, 2023
Earnings Flash (ME) 23ANDME Reports Q2 Revenue $50M, vs. Street Est of $56.8M MT
23andMe Holding Co. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
23Andme Holding Co. Reaffirms Earnings Guidance for the Year 2024 CI
More news
1 day+6.11%
1 week-12.52%
Current month-17.39%
1 month-39.45%
3 months-45.43%
6 months-53.83%
Current year-48.45%
More quotes
1 week
0.43
Extreme 0.4259
0.53
1 month
0.43
Extreme 0.4259
0.76
Current year
0.43
Extreme 0.4259
0.96
1 year
0.43
Extreme 0.4259
2.32
3 years
0.43
Extreme 0.4259
13.68
5 years
0.43
Extreme 0.4259
18.16
10 years
0.43
Extreme 0.4259
18.16
More quotes
Managers TitleAgeSince
Founder 50 05-12-31
Director of Finance/CFO 61 22-08-31
Chief Tech/Sci/R&D Officer 53 19-12-31
Members of the board TitleAgeSince
Director/Board Member 50 21-06-15
Director/Board Member 70 21-06-15
Director/Board Member 50 21-06-15
More insiders
Date Price Change Volume
24-03-18 0.4709 +6.11% 9,410,377
24-03-15 0.4438 -0.96% 7,467,933
24-03-14 0.4481 -9.69% 7,882,253
24-03-13 0.4962 -1.02% 6,179,027
24-03-12 0.5013 -6.87% 6,138,992

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4709 USD
Average target price
1.425 USD
Spread / Average Target
+202.61%
Consensus
  1. Stock
  2. Equities
  3. Stock 23andMe Holding Co. - Nasdaq